BridgeBio Pharma reported third-quarter net revenues of $353.2 million, driven by a $145 million year-over-year increase in Attruby product sales and a $75 million Bayer sales milestone. The company recorded a net loss attributable to common stockholders of $83.0 million, or $0.42 per share. To fund upcoming launches and operations, BridgeBio issued $632.5 million in principal amount of 1.95% senior notes due 2033. Cash, cash equivalents, and marketable securities totaled $1.5 billion as of September 30, 2026. The company operates as a commercial-stage biopharmaceutical firm developing medicines for genetic conditions.
